Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | F13A1 | P00488 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | TGM1 | P22735 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524534 | 0.88 | HDAC1 (0.39) | ALDH1A1KDM4ESMN1; SMN2HRH1L3MBTL1 | |
| SCHEMBL19384145 | 0.86 | HDAC1 (0.38) | ALDH1A1KDM4ESMN1; SMN2HRH1L3MBTL1 | |
| SCHEMBL19384156 | 0.85 | CTSL (0.38) | ALDH1A1KDM4ESMN1; SMN2HRH1TP53 | |
| Trifluoroacetic Acid SCHEMBL523116 | 0.82 | RBP4 (0.39) | ALDH1A1KDM4EHRH1TP53HDAC1 | |
| SCHEMBL20854266 | 0.78 | F13A1 (0.39) | ALDH1A1KDM4ETP53F13A1TGM2 | |
| SCHEMBL29777971 | 0.78 | ALDH1A1 (0.43) | ALDH1A1KDM4EHRH1L3MBTL1RBP4 | |
| SCHEMBL19384151 | 0.77 | HRH1 (0.46) | ALDH1A1KDM4ESMN1; SMN2HRH1F13A1 | |
| SCHEMBL10102481 | 0.77 | HRH1 (0.40) | ALDH1A1KDM4ESMN1; SMN2HRH1L3MBTL1 | |
| SCHEMBL524847 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4ESMN1; SMN2HRH1TP53 | |
| SCHEMBL7367495 | 0.75 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1F13A1TGM2TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017162304-A1 | CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA UK LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8969350-B2 | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | ASTRAZENECA AB (SE) | 2015-03-03 | — | — | US | disclosed |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | ASTRAZENECA UK LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | NR3C2, GRK4, PTGER2 | ALDH1A1 1934/4885KDM4E 2414/4885SMN1; SMN2 3152/4885 |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | NR3C2, ARRB1, GRK4 | ALDH1A1 1798/4885KDM4E 2556/4885SMN1; SMN2 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.